OncoTherapy Science, Inc. (FRA:30O)

Germany · Delayed Price · Currency is EUR

0.0775

+0.0010 (1.31%)

Last updated: Oct 23, 2026, 9:00 PM CEST

Market Cap	39.52M -4.7%
Revenue (ttm)	4.18M -8.7%
Net Income	-4.76M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	490
Open	0.0775
Previous Close	0.0765
Day's Range	0.0775 - 0.0775
52-Week Range	0.0640 - 0.1640
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company’s development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-cli... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 46

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 30O

Financial Performance

In fiscal year 2026, OncoTherapy Science's revenue was 808.00 million, an increase of 7.73% compared to the previous year's 750.00 million. Losses were -910.00 million, 11.7% more than in 2025.

Financial numbers in JPY Financial Statements